iRhythm Holdings, Inc. (IRTC) by event type
IRTC moves most on analyst upgrades — a median of -0.26% at 30 minutes across 21 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the IRTC overview →
How IRTC reacts across 5 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,081 of 2,717 | 21 | -0.26% | 43% | +1.15% |
| Coverage initiations 911 of 2,283 | 15 | +0.09% | 60% | +0.43% |
| Rating reiterations 2,295 of 3,522 | 94 | -0.06% | 48% | -0.19% |
| Price-target raises 1,469 of 1,790 | 37 | -0.15% | 41% | +0.02% |
| Price-target cuts 476 of 1,527 | 29 | +0.07% | 52% | -0.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 1 further class was observed with fewer than 10 measured events and is not published.
That’s how IRTC usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Coverage initiations → · Rating reiterations → · Price-target raises → · Price-target cuts → · IRTC overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Neovasc Inc. - Common Shares (NVCN) | 1,136 | -0.47% | 37% |
| Iovance Biotherapeutics, Inc. (IOVA) | 1,135 | +0.11% | 51% |
| GENOMIC HEALTH (GHDX) | 1,111 | 0.00% | 49% |
| INDIVIOR PLC S/ADR (INVVY) | 1,105 | 0.00% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.